BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/29/2026 8:41:41 AM | Browse: 140 | Download: 478
Publication Name World Journal of Transplantation
Manuscript ID 118962
Country Italy
ISSN 2220-3230 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © Author(s) (or their employer(s)) 2026. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Surgery
Manuscript Type Correspondence
Article Title Letter to the Editor: Induction therapy as a long-term commitment: Lessons from comparative outcomes of alemtuzumab and basiliximab
Manuscript Source Invited Manuscript
All Author List Luca Galassi, Erica Altamura, Lina Azzahrani, Federica Facchinetti and Matteo Lino Ravini
ORCID
Author(s) ORCID Number
Luca Galassi http://orcid.org/0000-0003-2580-1704
Erica Altamura http://orcid.org/0009-0004-1990-0882
Federica Facchinetti http://orcid.org/0009-0006-0970-3409
Matteo Lino Ravini http://orcid.org/0009-0001-4802-6088
Funding Agency and Grant Number
Corresponding Author Luca Galassi, Lecturer, MD, Researcher, Postgraduate School of Vascular and Endovascular Surgery, University of Milan, Festa del Perdono Street, Milan 20122, Lombardy, Italy. luca.galassi@unimi.it
Key Words Kidney transplantation; Induction therapy; Alemtuzumab; Basiliximab; Graft survival; Immunological debt; Precision medicine; Patient safety
Core Tip The choice of induction therapy in kidney transplantation has commonly been centered around short-term rejection outcomes, which do not reliably predict the long-term safety and graft outcomes. Evidence reveals that, despite similar rejection rates, alemtuzumab is associated with increased risks of infection and malignancy and reduced graft survival among standard-risk recipients. These data support a risk-stratified approach to induction therapy, advocating non-lymphocyte-depleting agents for standard-risk patients and reserving lymphocyte-depleting induction for selected high-risk recipients.
Publish Date 2026-05-29 08:41
Citation

Galassi L, Altamura E, Azzahrani L, Facchinetti F, Ravini ML. Letter to the Editor: Induction therapy as a long-term commitment: Lessons from comparative outcomes of alemtuzumab and basiliximab. World J Transplant 2026; 16(2): 118962

URL https://www.wjgnet.com/2220-3230/full/v16/i2/118962.htm
DOI https://dx.doi.org/10.5500/wjt.v16.i2.118962
Full Article (PDF) WJT-16-118962-with-cover.pdf